Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.

Cancer research - 15 Oct 2015

Yoo Byunghee, Kavishwar Amol, Ross Alana, Wang Ping, Tabassum Doris P, Polyak Kornelia, Barteneva Natalia, Petkova Victoria, Pantazopoulos Pamela, Tena Aseda, Moore Anna, Medarova Zdravka

Abstract excerpt

The therapeutic promise of microRNA (miRNA) in cancer has yet to be realized. In this study, we identified and therapeutically exploited a new role for miR-10b at the metastatic site, which links its overexpression to tumor cell viability and proliferation. In the protocol developed, we combined a miR-10b-inhibitory nanodrug with low-dose anthracycline to achieve complete durable regressions of metastatic disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Gene Knockout Techniques

Share to Nanoparticles

Share to Neoplasm Metastasis

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26359455
DOI: 10.1158/0008-5472.CAN-15-0888
PMCID: PMC4609288

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.PMID 26359455Read ↗

Targeting metastatic breast cancer: problems and potentialSemantic proximity Read ↗

Significance of metastamiR-10b in breast cancer therapeuticsSemantic proximity Read ↗

Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents.Semantic proximity Read ↗

Two-In-One: Combined Targeted Chemo and Gene Therapy for Tumor Suppression and Prevention of MetastasesSemantic proximity Read ↗

Microtubule Disruption Reduces Metastasis More Effectively Than Primary Tumor GrowthSemantic proximity Read ↗

miR-197-5p increases Doxorubicin-mediated anticancer cytotoxicity of HT1080 fibrosarcoma cells by decreasing drug effluxSemantic proximity Read ↗

Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation.Semantic proximity Read ↗

Non-coding RNA as mediators in microenvironment-breast cancer cell communication.Semantic proximity Read ↗

Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus.Semantic proximity Read ↗

Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancerSemantic proximity Read ↗

Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation.Semantic proximity Read ↗

Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.